# Matthew Meyerson

Source: https://onco.cc/people/matthew-meyerson/  
OnCo record `matthew-meyerson` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Co-discovered EGFR mutations in lung cancer and linked Fusobacterium to colorectal cancer.

## Summary

Matthew Meyerson is Director of the Center for Cancer Genomics at Dana-Farber and an Institute Member of the Broad Institute of MIT and Harvard. He is a genomicist known for co-discovering EGFR mutations in lung cancer in 2004, mapping lung adenocarcinoma genomes for The Cancer Genome Atlas, and identifying enrichment of Fusobacterium nucleatum in colorectal tumours. His selected papers report EGFR mutations in lung cancer correlating with response to gefitinib, and the genomic analysis associating Fusobacterium with colorectal carcinoma. He continues to work on lung cancer genomics and the microbiome in cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Center for Cancer Genomics, Dana-Farber; Institute Member, Broad
- Specialisms: Lung cancer genomics; EGFR mutations; Microbiome and cancer

## Sources

- Broad bio: https://www.broadinstitute.org/bios/matthew-meyerson
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Meyerson%20M%5BAuthor%5D

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- institutions: [Broad Institute of MIT and Harvard](https://onco.cc/institutions/broad-institute/)
- key papers: [Comprehensive molecular profiling of lung adenocarcinoma](https://onco.cc/key-papers/paper-tcga-lung-adenocarcinoma-nature-2014/), [Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas](https://onco.cc/key-papers/paper-campbell-pan-lung-somatic-alterations-nat-genet-2016/), [EGFR mutation and resistance of non-small-cell lung cancer to gefitinib](https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/), [EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy](https://onco.cc/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/)

---
JSON: https://onco.cc/api/v1/entities/matthew-meyerson.json